These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29420119)

  • 1. Cross-protection induced by VA-MENGOC-BC® vaccine.
    Ochoa-Azze RF
    Hum Vaccin Immunother; 2018 May; 14(5):1064-1068. PubMed ID: 29420119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of meningococcal group B OMV vaccines, beyond their brief.
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
    Sierra-González VG
    MEDICC Rev; 2019 Oct; 21(4):19-27. PubMed ID: 32335565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
    Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
    Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meningococcal B vaccine induces cross-protection against gonorrhea.
    Azze RFO
    Clin Exp Vaccine Res; 2019 Jul; 8(2):110-115. PubMed ID: 31406692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
    Sifontes S; Infante JF; Pérez P; Caro E; Sierra G; Campa C
    Arch Med Res; 1997; 28(1):41-5. PubMed ID: 9078586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
    Wang B; Mohammed H; Andraweera P; McMillan M; Marshall H
    J Infect; 2024 Sep; 89(3):106225. PubMed ID: 38986746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
    Masforrol Y; Gil J; García D; Noda J; Ramos Y; Betancourt L; Guirola O; González S; Acevedo B; Besada V; Reyes O; González LJ
    Hum Vaccin Immunother; 2017 Nov; 13(11):2548-2560. PubMed ID: 29083947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into Prevention of Neisseria Gonorrhoeae: A Short Review.
    La Fauci V; Lo Giudice D; Squeri R; Genovese C
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423044
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
    Williams JN; Weynants V; Poolman JT; Heckels JE; Christodoulides M
    Vaccine; 2014 Mar; 32(11):1280-6. PubMed ID: 24486354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [VA-MENGOC-BC vaccine: its impact on meningococcal disease in children 1-4 years old].
    Pérez Rodríguez A; Meneses FO
    Rev Cubana Med Trop; 1999; 51(3):189-93. PubMed ID: 10887587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the Co-Administration of Heptavalent Conjugate Vaccine PCV7-TT on the Immunological Response Elicited by VA-MENGOC-BC® and Heberpenta®-L in Rabbits.
    Espinosa-Viñals C; García-Rivera D; Rodríguez Noda L; Amador Gómez A; Nicot M; Valle O; Núñez JF; Martin Y; Santana D; Valdés Y; Vérez Bencomo V
    Immunol Invest; 2017 May; 46(4):395-408. PubMed ID: 28379053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Author reply to VA-MENGOC-BC cross-protection (2018HV0022).
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1069. PubMed ID: 29659326
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of the anti-meningococcal vaccine VA-MENGO-BC in the first year of life of Cuban children, 1997-2008].
    Pérez Rodríguez A; Dickinson Meneses F; Rodríguez Ortega M
    Rev Cubana Med Trop; 2011; 63(2):155-60. PubMed ID: 23437524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunogenecity induced by the VA-MENGOC-BC antimeningococcal vaccine against the ATCC C11. N. meningitidis strain in adolescents 12 years after being vaccinated].
    Camaraza MA; Ochoa R; Arnet AG; Sotolongo F; Martínez I; Cuevas I; Hernández D
    Rev Cubana Med Trop; 2004; 56(1):26-30. PubMed ID: 15849905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.